IMAD ASAAD
Allopathic & Osteopathic Physicians|Internal Medicine|Gastroenterology CLEVELAND, OH NPI 1669725057
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Gastroenterology OH Madrigal Pharmaceuticals All categories
General Payments — all program years on this page
$33,503.09
- Category: General Payments
- Program years: PY2018–2024
- Record count: 208
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $30,967.81 across 106 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $26,086.00 | 5 |
| Food and Beverage | $2,523.73 | 92 |
| Travel and Lodging | $2,358.08 | 9 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Madrigal Pharmaceuticals | $29,377.82 | 25 |
| ABBVIE INC. | $430.37 | 32 |
| Gilead Sciences, Inc. | $420.50 | 20 |
| Ipsen Biopharmaceuticals, Inc | $253.25 | 4 |
| GENZYME CORPORATION | $87.20 | 5 |
| Phathom Pharmaceuticals, Inc. | $53.03 | 3 |
| Novo Nordisk AS | $47.65 | 1 |
| Janssen Biotech, Inc. | $45.11 | 2 |
| Lilly USA, LLC | $42.89 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $42.35 | 2 |
| INTERCEPT PHARMACEUTICALS, INC. | $39.12 | 2 |
| Celgene Corporation | $32.01 | 2 |
| QOL Medical, LLC | $30.24 | 2 |
| Sandoz Inc. | $18.59 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18.02 | 1 |
| Merck Sharp & Dohme Corporation | $15.70 | 1 |
| Regeneron Healthcare Solutions, Inc. | $13.96 | 1 |
By program year
Records — PY2024 (106)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.